Solid dispersions: A strategy for poorly aqueous soluble drugs and technology updates

Expert Opinion on Drug Delivery

Volumn 9, Issue 11, 2012, Pages 1419-1440

  Alam, Mohd Aftab ^a   Ali, Raisuddin ^a   Al Jenoobi, Fahad Ibrahim ^a   Al Mohizea, Abdullah M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Bioavailability; Dissolution; Solid dispersion; Solubility

Indexed keywords

ACECLOFENAC; ARTEMETHER; CARBOMER; CARVEDILOL; CELECOXIB; CYCLOSPORIN; CYCLOSPORIN A; DOCETAXEL; ETHENZAMIDE; ETORICOXIB; GLICLAZIDE; GRISEOFULVIN; INDOMETACIN; IRBESARTAN; ITRACONAZOLE; MELOXICAM; MEVINOLIN; NIFEDIPINE; NILVADIPINE; NITRENDIPINE; OFLOXACIN; PARACETAMOL; PREDNISOLONE; PROMETHAZINE; ROFECOXIB; SALBUTAMOL SULFATE; SIBUTRAMINE; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CLOSED CYCLE SPRAY DRYING; DISPERSION; DRUG DELIVERY SYSTEM; DRUG STABILITY; SOLID DISPERSION;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84867825837     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.732064     Document Type: Article

References (171)

1. Nabekura T, Ito Y, Cai H, et al. Preparation and in-vivo ocular absorption studies of disulfiram solid dispersion. Biol Pharm Bull 2000;23:616-20 (Pubitemid 30321283)
2. Papageorgiou GZ, Papadimitriou S, Karavas E, et al. Improvement in chemical and physical stability of fluvastatin drug through hydrogen bonding interactions with different polymer matrices. Curr Drug Deliv 2009;6:101-12
3. Sahoo J, Murthy PN, Biswal S, Manik Formulation of sustained-release dosage form of verapamil hydrochloride by solid dispersion technique using Eudragit RLPO or Kollidon-SR. AAPS PharmSciTech 2009;10:27-33
4. Madgulkar A, Kadam S, Pokharkar V. Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. AAPS Pharm Sci Tech 2008;9:998-1005
5. Takeuchi H, Nagira S, Tanimura S, et al. Tabletting of solid dispersion particles consisting of indomethacin and porous silica particles. Chem Pharm Bull 2005;53:487-91 (Pubitemid 40740614)
6. Dobaria NB, Badhan AC, Mashru RC. A Novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization. AAPS Pharm Sci Tech 2009;10:951-9
7. Zijlstra GS, Rijkeboer M, Jan van Drooge D, et al. Characterization of a cyclosporine solid dispersion for inhalation. AAPS J 2007;9:E190-9 (Pubitemid 47007410)
8. Desai KG, Mallery SR, Schwendeman SP. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DLlactide-co- glycolide) implants. Eur J Pharm Biopharm 2008;70:187-98
9. Onoue S, Sato H, Kawabata Y, et al. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release 2009;138(1):16-23
10. Shimpi SL, Mahadik KR, Paradkar AR. Study on mechanism for amorphous drug stabilization using Gelucire 50/13. Chem Pharm Bull 2009;57:937-42
11. Sugamura Y, Fujii M, Nakanishi S, et al. Effect of particle size of drug on conversion of crystals to an amorphous state in a solid dispersion with crospovidone. Chem Pharm Bull 2011;59:235-8
12. Yuebin GE. An investigation into the mechanisms of rapid release of standard extract from Ginkgo biloba leaf in polyethylene glycol 6000 solid dispersions. Yakugaku Zasshi 2010;130:425-30
13. Kovacic B, Vrecer F, Planinsek O. Solid dispersions of carvedilol with porous silica. Chem Pharm Bull 2011;59:427-33
14. Dahlberg C, Millgyist-Fureby A, Schuleit M. Surface composition and contact angle relationship for differently prepared solid dispersions. Eur J Pharm Biopharm 2008;70:478-85
15. Leonardi D, Barrera MG, Lamas MC, Salomo'n CJ. Development of Prednisone:polyethylene Glycol 6000 fast-release tablets from solid dispersions: solid-state characterization, dissolution behavior, and formulation parameters. AAPS Pharm Sci Tech 2007;8:E1-8
16. Jain SK, Shukla M, Shrivastava V. Development and in vitro evaluation of ibuprofen mouth dissolving tablets using solid dispersion technique. Chem Pharm Bull 2010;58:1037-42
17. Valizadeh H, Nokhodchi A, Qarakhani N, et al. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev Ind Pharm 2004;30:303-17 (Pubitemid 38451755)
18. Boghra RJ, Kothawade PC, Belgamwar VS, et al. Solubility, dissolution rate and bioavailability enhancement of irbesartan by solid dispersion technique. Chem Pharm Bull 2011;59:438-41
19. Chen R, Tagawa M, Hoshi N, et al. Improved dissolution of an insoluble drug using a 4-fluid nozzle spray-drying technique. Chem Pharm Bull 2004;52:1066-70 (Pubitemid 41679544)
20. Ghareeb MM, Abdulrasool AA, Hussein AA, Noordin MI. Kneading technique for preparation of binary solid dispersion of meloxicam with Poloxamer 188. AAPS Pharm Sci Tech 2009;10:1206-15
21. EL-Badry M. Physicochemical characterization and dissolution properties of Meloxicam-Gelucire 50/13 Binary Systems. Sci Pharm 2011;79:375-86
22. Fouad EA, EL-Badry M, Mahrous GM, et al. The use of spray-drying to enhance celecoxib solubility. Drug Dev Ind Pharm 2011;37:1463-72
23. Al-Hamidi H, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B Biointerfaces 2010;76:170-8
24. Rane Y, Mashru R, Sankalia M, Sankalia J. Effect of hydrophilic swellable polymers on dissolution enhancement of carbamazepine solid dispersions studied using response surface methodology. AAPS Pharm Sci Tech 2007;27:E1-E11 (Pubitemid 46620643)
25. Ghosh I, Snyder J, Vippagunta R, et al. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder. Int J Pharm 2011;419:12-19
26. Feng J, Xu L, Gao R, et al. Evaluation of polymer carriers with regard to the bioavailability enhancement of bifendate solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm 2012;38(6):735-43
27. Zheng X, Yang R, Zhang Y, et al. Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm 2007;33:783-9 (Pubitemid 47123804)
28. Shen SC, Ng WK, Chia L, et al. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. Int J Pharm 2011;410:188-95
29. Broman E, Khoo C, Taylor LS. A comparison of alternative polymer excipients and processing methods for making solid dispersions of poorly water soluble drugs. Int J Pharm 2001;222:139-51 (Pubitemid 32525795)
30. Karavas S, Georgarakis E, Sigalas MP, et al. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 2007;66:334-47 (Pubitemid 46778978)
31. Okonogi S, Puttipipatkhachorn S. Dissolution improvement of high drug-loaded solid dispersion. AAPS PharmSciTech 2006;7:E1-6 (Pubitemid 43884216)
32. Hughey JR, DiNunzio JC, Bennett RC, et al. Dissolution enhancement of a drug exhibiting thermal and acidic decomposition characteristics by fusion processing: A comparative study of hot melt extrusion and KinetiSol dispersing. AAPS Pharm Sci Tech 2010;11(2):760-74
33. Patel M, Tekade A, Gattani S, Surana S. Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques. AAPS Pharm Sci Tech 2008;9:1262-9
34. Hirasawa N, Ishise S, Miyata H, Danjo K. Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers. Chem Pharm Bull 2004;52:244-7 (Pubitemid 41656758)
35. Chen R, Okamoto H, Danjo K. Preparation of functional composite particles of salbutamol sulfate using a 4-Fluid Nozzle Spray-Drying Technique. Chem Pharm Bull 2008;56:254-9 (Pubitemid 351463233)
36. Ozawa M, Hasegawa K, Yonezawa Y, Sunada H. Preparation of solid dispersion for ethenzamide-carbopol and theophylline-carbopol systems using a twin screw extruder. Chem Pharm Bull 2002;50:802-7 (Pubitemid 41694898)
37. Xu L, Li SM, Sunada H. Preparation and evaluation of ibuprofen solid dispersion systems with kollidon particles using a pulse combustion dryer system. Chem Pharm Bull 2007;55:1545-50 (Pubitemid 350126158)
38. Moneghini M, De Zordi N, Solinas D, et al. Characterization of solid dispersions of itraconazole and vitamin E TPGS prepared by microwave technology. Future Med Chem 2010;2:237-46
39. Maurya D, Belgamwar V, Tekade A. Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium. J Pharm Pharmacol 2010;62:1599-606
40. Park JH, Yan YD, Chi SC, et al. Preparation and evaluation of cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process. J Pharm Pharmacol 2011;63:491-9
41. Tong HH, Du Z, Wang GN, et al. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS class IV compound. Int J Pharm 2011;404:148-58
42. Garcia-Rodriguez JJ, de la Torre-Iglesias PM, Vegas-Sa'nchez MC, et al. Changed crystallinity of mebendazole solid dispersion: improved anthelmintic activity. Int J Pharm 2011;403:23-8
43. Dang YJ, Hu CH, An LN, Zhu CY. Study of the physicochemical properties and oral bioavailability of the solid dispersion of cantharidin with polyethylene glycol 4000. Methods Find Exp Clin Pharmacol 2010;32:157-62
44. DiNunzio JC, Brough C, Miller DA, et al. Applications of KinetiSol dispersing for the production of plasticizer free amorphous solid dispersions. Eur J Pharm Sci 2010;40:179-87
45. Maghsoodi M, Sadeghpoor F. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique. Drug Dev Ind Pharm 2010;36:917-25
46. Bashiri-Shahroodi A, Nassab PR, Szabó-Re've'sz P, Rajkó R. Preparation of a solid dispersion by a dropping method to improve the rate of dissolution of meloxicam. Drug Dev Ind Pharm 2008;34:781-8 (Pubitemid 351962351)
47. Ugaonkar S, Nunes AC, Needham TE. Effect of n-scCO(2) on crystalline to amorphous conversion of carbamazepine. Int J Pharm 2007;333:152-61 (Pubitemid 46283281)
48. Overhoff KA, Moreno A, Miller DA, et al. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int J Pharm 2007;336(1):122-32 (Pubitemid 46551563)
49. Barakat NS. Etodolac-liquid-filled dispersion into hard gelatin capsules: An approach to improve dissolution and stability of etodolac formulation. Drug Dev Ind Pharm 2006;32:865-76 (Pubitemid 44266771)
50. Al-Obaidi H, Brocchini S, Buckton G. Anomalous properties of spray dried solid dispersions. J Pharm Sci 2009;98:4724-37
51. Huang J, Li Y, Wigent RJ, et al. Interplay of formulation and process methodology on the extent of nifedipine molecular dispersion in polymers. Int J Pharm 2011;420:59-67
52. Sonali D, Tejal S, Vaishali T, Tejal G. Silymarin solid dispersions: characterization and influence of preparation methods on dissolution. Acta Pharm 2010;60:427-43
53. Wu K, Li J, Wang W, Winstead DA. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J Pharm Sci 2009;98:2422-31
54. van Drooge DJ, Hinrichs WL, Wegman KA, et al. Solid dispersions based on inulin for the stabilisation and formulation of delta 9-tetrahydrocannabinol. Eur J Pharm Sci 2004;21(4):511-18 (Pubitemid 38283925)
55. McGinity JW, Maincent P, Steinfink H. Crystallinity and dissolution rate of tolbutamide solid dispersions prepared by the melt method. J Pharm Sci 1984;73:1441-4 (Pubitemid 14021903)
56. Collett JH, Flood BL, Sale FR. Some factors influencing dissolution rate from salicylic acid-urea solid dispersions. J Pharm Pharmcol 1976;28:305-8
57. Ghareeb MM, Abdulrasool AA, Hussein AA, Noordin MI. Kneading technique for preparation of binary solid dispersion of meloxicam with poloxamer 188. AAPS Pharm Sci Tech 2009;10(4):1206-15
58. Dobry DE, Settell DM, Baumann JM, et al. A model-based methodology for spray-drying process development. J Pharm Innov 2009;4(3):133-42
59. Kim EJ, Chun MK, Jang JS, et al. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur J Pharm Biopharm 2006;64(2):200-5
60. Wu JX, Yang M, Berg Fv, et al. Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. Eur J Pharm Sci 2011;44(5):610-20
61. Zawar LR, Bari SB. Preparation, characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion. Chem Pharm Bull 2012;60(4):482-7
62. Nakamichi K, Nakano T, Yasuura H, et al. The role of kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin-screw extruder. Int J Pharm 2002;241(2):203-11 (Pubitemid 34718022)
63. Moneghini M, Zingone G, De Zordi N. Influence of the microwave technology on the physical-chemical properties of solid dispersion with nimesulide. Powder Technol 2009;195:259-63
64. Moneghini M, Bellich B, Baxa P, Princivalle F. Microwave generated solid dispersions containing ibuprofen. Int J Pharm 2008;361(1-2):125-30
65. Kanakam VB. Enhancement of dissolution rate of atorvastatin calcium using solid dispersions by dropping method. Int J Pharm Tech Res 2011;3(2):652-9
66. Hu J, Rogers TL, Brown J, et al. Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. Pharm Res 2002;19(9):1278-84
67. Rogers TL, Nelsen AC, Sarkari M, et al. Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: spray-freezing into liquid with atmospheric freeze-drying. Pharm Res 2003;20(3):485-93 (Pubitemid 36292193)
68. He X, Pei L, Tong HH, Zheng Y. Comparison of spray freeze drying and the solvent evaporation method for preparing solid dispersions of baicalein with Pluronic F68 to improve dissolution and oral bioavailability. AAPS Pharm Sci Tech 2011;12(1):104-13
69. Betageri GV, Makarla KR. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int J Pharm 1995;126(1-2):155-60 (Pubitemid 26015632)
70. Moes JJ, Koolen SL, Huitema AD, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm 2011;420(2):244-50
71. Badens E, Majerik V, Horvath G, et al. Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies. Int J Pharm 2009;377(1-2):25-34
72. De Zordi N, Moneghini M, Kikic I, et al. Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions. Eur J Pharm Biopharm 2012;81(1):131-41
73. Moneghini M, Kikic I, Voinovich D, et al. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: Preparation, characterisation, and in vitro dissolution. Int J Pharm 2001;222(1):129-38 (Pubitemid 32525794)
74. Purvis T, Mattucci ME, Crisp MT, et al. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS Pharm Sci Tech 2007;8(3):E58
75. Overhoff KA, McConville JT, Yang W, et al. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res 2008;25(1):167-75
76. Wang L, Cui FD, Sunada H. Improvement of the dissolution rate of nitrendipine using a new pulse combustion drying method. Chem Pharm Bull (Tokyo)2007;55(8):1119-25 (Pubitemid 47344960)
77. Available from: http://www.pulsedry. com/tech.php
78. Kattige A, Rowley G. The effect of poloxamer viscosity on liquid-filling of solid dispersions in hard gelatin capsules. Drug Dev Ind Pharm 2006;32(8):981-90 (Pubitemid 44359760)
79. Patel MM, Patel DM. Fast dissolving valdecoxib tablets containing solid dispersion of valdecoxib. Indian J Pharm Sci 2006;68(2):222-5
80. Bikiaris DN. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 2011;8(11):1501-19
81. Bikiaris DN. Solid Dispersions, Part II: new strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 2011;8(12):1663-80
82. Patel AR, Joshi VY. Evaluation of SLS: APG mixed surfactant systems as carrier for solid dispersion. AAPS PharmSciTech 2008;9:583-90
83. Bley H, Fussnegger B, Bodmeier R. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm 2010;390:165-73
84. Zhu Q, Taylor LS, Harris MT. Evaluation of the microstructure of semicrystalline solid dispersions. Mol Pharm 2010;7(4):1291-300
85. Zidan AS, Rahman Z, Sayeed V, et al. Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis. Int J Pharm 2012;423(2):341-50
86. de Waard H, Hessels MJ, Boon M, et al. CLSM as quantitative method to determine the size of drug crystals in a solid dispersion. Pharm Res 2011;28:2567-74
87. Aso Y, Yoshioka S, Miyazaki T, et al. Miscibility of nifedipine and hydrophilic polymers as measured by 1H-NMR Spin-Lattice Relaxation. Chem Pharm Bull 2007;55:1227-31 (Pubitemid 47344979)
88. Zhang J, Bunker M, Chen X, et al. Nanoscale thermal analysis of pharmaceutical solid dispersions. Int J Pharm 2009;380:170-3
89. Li L, AbuBaker O, Shao ZJ. Characterization of poly(ethylene oxide) as a drug carrier in hot-melt extrusion. Drug Dev Ind Pharm 2006;32:991-1002 (Pubitemid 44359761)
90. Lauer ME, Grassmann O, Siam M, et al. Atomic Force Microscopy-based screening of drug-excipient miscibility and stability of solid dispersions. Pharm Res 2011;28:572-84
91. Rumondor AC, Ivanisevic I, Bates S, et al. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm Res 2009;26:2523-34
92. Tobyn M, Brown J, Dennis AB, et al. Amorphous drug-PVP dispersions: Application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. J Pharm Sci 2009;98:3456-68
93. Baird JA, Taylor LS. Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv Drug Deliv Rev 2012;64(5):396-421
94. Tran PH, Tran TT, Park JB, et al. Investigation of physicochemical factors affecting the stability of a pH-modulated solid dispersion and a tablet during storage. Int J Pharm 2011;414:48-55
95. Kanaujia P, Lau G, Ng WK, et al. Nanoparticle formation and growth during in vitro dissolution of ketoconazole solid dispersion. J Pharm Sci 2011;100:2876-85
96. Rumondor AC, Wikstrom H, Van Eerdenbrugh B, Taylor LS. Understanding the tendency of amorphous solid dispersions to undergo amorphous-amorphous phase separation in the presence of absorbed moisture. AAPS PharmSciTech 2011;12(4):1209-19
97. Six K, Verreck G, Peeters J, et al. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 2004;93:124-31 (Pubitemid 38081820)
98. Verreck G, Six K, Van den Mooter G, et al. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part 1. Int J Pharm 2003;251:165-74 (Pubitemid 36071471)
99. Hirasawa N, Ishise S, Miyata H, Danio K. An attempt to stabilize nilvadipine solid dispersion by the use of ternary systems. Drug Dev Ind Pharm 2003;29(9):997-1004 (Pubitemid 37346101)
100. Pajula K, Taskinen M, Lehto VP, et al. Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram. Mol Pharm 2010;7(3):795-804
101. Janssens S, Van den Mooter G. Review: Physical chemistry of solid dispersions. J Pharm Pharmacol 2009;61(12):1571-86
102. Ozeki T, Yuasa H, Okada H. Controlled release of drug via methylcellulose-carboxyvinylpolymer interpolymer complex solid dispersion. AAPS Pharm Sci Tech 2005;6(2):E231-6
103. Ozeki T, Yuasa H, Kanaya Y. Controlled release from solid dispersion composed of poly(ethylene oxide)-carbopol interpolymer complex with various cross-linking degrees of carbopol. J Control Release 2000;63(3):287-95
104. Tran HT, Park JB, Hong KH, et al. Preparation and characterization of pH-independent sustained release tablets containing solid dispersion granules of a poorly water-soluble drug. Int J Pharm 2011;415(1-2):83-8
105. Varshosaz J, Ahmadi F, Emami J, et al. Colon delivery of budesonide using solid dispersion in dextran foe the treatment and secondary prevention of ulcerative colitis in rat. Int J Prev Med 2010;1(2):115-23
106. Tran PH, Tran TT, Lee KH, et al. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility. Expert Opin Drug Deliv 2010;7:647-61
107. Tran TT, Tran PH, Choi HG, et al. The role of acidifiers in solid dispersions and physical mixtures. Int J Pharm 2010;384:60-6
108. Tanaka N, Imai K, Okimoto K, et al. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nivadipine (II): in vivo evaluation. J Control Release 2006;112(1):51-6
109. Dangprasirt P, Pongwai S. Development of diclofenac sodium controlled release solid dispersion powders and capsules by freeze drying technique using ethylcellulose and chitosan as carriers. Drug Dev Ind Pharm 1998;24:947-53 (Pubitemid 28470971)
110. Quinten T, De Beer T, Almeida A, et al. Development and evaluation of injection-molded sustained-release tablets containing ethylcellulose and polyethylene oxide. Drug Dev Ind Pharm 2011;37:149-59
111. Chen H, Jiang G, Ding F. Monolithic osmotic tablet containing solid dispersion of 10-hydroxycamptothecin. Drug Dev Ind Pharm 2009;35:131-7
112. Dahiya S, Pathak K, Sharma R. Development of extended release coevaporates and coprecipitates of promethazine HCl with acrylic polymers: formulation considerations. Chem Pharm Bull (Tokyo) 2008;56:504-8 (Pubitemid 351520134)
113. Cui F, Yang M, Jiang Y, et al. Design of sustained-release nitrendipine microspheres having solid dispersion structure by quasi-emulsion solvent diffusion method. J Control Release 2003;91(3):375-84 (Pubitemid 36976768)
114. Chen D, Tsay RJ, Lin HI, et al. Stabilization and sustained-release effect of misoprostol with methacrylate copolymer. Int J Pharm 2000;203:141-8 (Pubitemid 30627634)
115. Sullivan MF, Kalkwarf DR. Sustained release of naltrexone from glyceride implants. Natl Inst Drug Abuse Res Monogr Ser 1976;4:27-32
116. Aly AM, Ali AS. Preparation and evaluation of glipizide tablets containing both enhanced and sustained release solid dispersions. IJPSN 2010;2(4):714-25
117. Available from: http://www.fujichemical. co.jp/images/whatsnew/uploads/ 2010/10/Fuji-Email-Blast-CSD-SEP09-2008.pdf\
118. Available from: http://xspray.com/technology.
119. Available from: http://www. karolinskadevelopment.com/portfolio/ pharmaceutical-formulation/xspraymicroparticles-ab/
120. Available from: http://www.smblab.be/index.php/formulation/lidose/121. Available from: http://www. ondrugdelivery.com/publications/Oral%202010/Mayne. pdf \
121. Available from: http://chemistry-today. teknoscienze.com/pdf/hardung- CaseStudy-EXCIPENTS2010. pdf
122. Linn M, Collnot EM, Djuric D, et al. Soluplus- as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur J Pharm Sci 2012;45(3):336-43
123. Available from: http://scidok.sulb.unisaarland. de/volltexte/2012/4551/ pdf/Linn-dissertation.pdf
124. Vadher AH, Parikh JR, Parikh RH, Solanki AB. Preparation and characterization of co-grinded mixtures of aceclofenac and Neusilin US2 for dissolution enhancement of aceclofenac. AAPS PharmSciTech 2009;10(2):606-14
125. Maclean J, Medina C, Daurio D, et al. Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin. J Pharm Sci 2011;100(8):3332-44
126. Hailu SA, Bonger RH. Effect of the pH grade of silicates on chemical stability of coground amorphous quinapril hydrochloride and its stabilization using pH-modifiers. J Pharm Sci 2009;98(9):3358-72
127. Available from: http://www.neusilin.com/multicms/neusilin/pdf/articles/ 26/fuji-emailblast-neusilin-sep09-v2.pdf
128. Bahl D, Bogner RH. Amorphization of indomethacin by co-grinding with Neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm Res 2006;23(10):2317-25 (Pubitemid 44511512)
129. Gupta MK, Vanwert A, Bogner RH. Formation of physically stable amorphous drugs by milling with Neusilin. J Pharm Sci 2003;92(3):536-51 (Pubitemid 36258968)
130. Available from: http://www. ondrugdelivery.com/publications/ Oral%20May%202011/Oral%20Drug%20Delivery%20May%202011%20lo%20res.pdf
131. Available from: http://www. ondrugdelivery.com/publications/Oral%202010/ Oral-Drug-Delivery-2010-ONdrugDelivery.pdf 133. Fujisawa Pharmaceutical Co., Ltd. Fast release solid preparation of dihydropyridine a compound. US4654206; 1987
132. Fujisawa Pharmaceutical Co., Ltd. Solid dispersion composition of FR-900506 substance. US4916138; 1990
133. The Population Council, Inc. Manufacture of long term contraceptive implant. US4244949; 1981
134. The Procter & Gamble Co. Solid dispersion compositions of tebufelone. US5281420; 1994
135. Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine. US5340591; 1994
136. Nippon Shinyaku Co, Ltd. Method of manufacturing solid dispersion. US5456923; 1995
137. L'Oreal. Process for the preparation of a solid dispersion of at least one polyhydric alcohol in a fatty body and the resulting dispersion for cosmetic and pharmaceutical use. US5580546; 1996
138. L'Oreal. Process for the preparation of a solid dispersion of at least one polyhydric alcohol in a fatty body and the resulting dispersion for cosmetic and pharmaceutical use. US5437859; 1995
139. Tanabe Seiyaku Co., Ltd. Method for producing sustained release microsphere preparation. US5556642; 1996
140. L'Oreal. Cosmetic composition in the form of a solid dispersion comprising a fatty phase, a polyhydric alcohol and colorless fillers. US5750120; 1998
141. Laboratoires Effik. Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions. US5776495; 1998
142. LOreal Anhydrous solid dispersion containing organoflourinated hydrocarbon compounds and its use in cosmetics. US5830444; 1998
143. Development Center for Biotechnology. Stabilization of prostaglandin drug. US5889051; 1999
144. Endo Pharmaceuticals, Inc. Process for manufacturing paroxetine solid dispersions. US5955475; 1999
145. Laboratoires Effik. Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions. US6027747; 2000
146. Akzo Nobel NV. Controlled release preparation. US6156343; 2000
147. Nissan Chemical Industries, Ltd. and Zeria Pharmaceutical Co., Ltd. Process for producing efonidipine hydrochloride preparations. US6171599; 2001
148. Novartis AG. Pharmaceutical compositions. US6197781; 2001
149. Novartis AG. Pharmaceutical compositions. US6599535; 2003
150. Jenapharm GmbH & Co. KG and LTS Lohmann Therapie-Systeme AG. Transdermal compositions with enhanced skin penetration properties. US6238284; 2001
151. Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer. US6254889; 2001
152. Finetex, Inc. Delivery system for inorganic sunscreens. US6261713; 2001
153. Sherman; Bernard Charles. Pharmaceutical composition comprising fenofibrate. US6444225; 2002
154. Mitsubishi Chemical Corporation. Solid dispersion containing sialic acid derivative. US6444649; 2002
155. Nissan Chemical Industries, Ltd. Method for converting sparingly water-soluble medical substance to amorphous state. US6462093; 2002
156. Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition. US6503927; 2003
157. Abbott GmbH & Co. KG. Test system for characterizing the compatibility of bioactive substances and polyvinylpyrrolidone. US6599931; 2003
158. Pfizer, Inc. Controlled release by extrusion of solid amorphous dispersions of drugs. US6706283; 2004
159. Bend Research, Inc. Controlled release by extrusion of solid amorphous dispersions of drugs. US7550158; 2009
160. Biochemie Gesellschaft m.b.H. Compositions comprising cefuroxime axetil. US6727243; 2004
161. Kowa Co., Ltd. Solid dispersion composition. US6753330; 2004
162. Shin-Etsu Chemical Co., Ltd. Process for producing a pharmaceutical solid preparation containing a poorly soluble drug. US6872336; 2005
163. F H Faulding & Co. Ltd. Pharmaceutical compositions for poorly soluble drugs. US6881745; 2005
164. Fujisawa Pharmaceutical Co., Ltd. Sustained release formulation containing tacrolimus. US6884433; 2005
165. Yamanouchi Pharmaceutical Co., Ltd. Rapidly disintegrable pharmaceutical composition. US6899899; 2005
166. Bayer HealthCare LLC. Solid phase dispersion of quinolone or naphthyridonecarboxylic acids. US7112336; 2006
167. Abbott Laboratories. Solid dispersion pharmaceutical formulations. US7364752; 2008
168. Sanofi-aventis U.S. LLC. Amorphous solid dispersions. US7713548; 2010
169. Lifecycle Pharma A/S. Solid dispersions comprising tacrolimus. US7994214; 2011
170. Knoll GmbH. Formulations of active components in the form of a solid dispersion. US8021688; 2011
171. Abbott Laboratories. Solid pharmaceutical dosage form. US8025899; 2011